The purpose of this study is to offer Panel Reactive Antibodies [PRA] reduction treatment to
high responder renal transplant patients who otherwise may never be compatible with a
potential organ donor. PRA reduction is offered in the following phases:
1. Immunological Testing
2. Transplant Nephrectomy
3. Pharmacologic Therapy
4. Plasmapheresis
5. Transplant